The Kingdom of the Netherlands
and
the European Medicines Agency,
Having regard to the Treaty on the European Union, in particular Protocol No 7 on the Privileges and Immunities of the European Union annexed to the Treaty on the European Union (hereinafter “the Protocol”), the Treaty on the Functioning of the European Union and the Treaty establishing the European Atomic Energy Community;
Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the
Council of 31 March 2004 laying down Community procedures for the authorization and
supervision of medicinal products for human and veterinary use and establishing a
European Medicines Agency;
Having regard to the decision of the Member States in the margins of the General Affairs
Council meeting of 20 November 2017 to relocate the seat of the European Medicines
Agency in Amsterdam, the Netherlands;
Whereas Article 74 of Regulation (EC) No. 726/2004 provides that the Protocol shall apply to the Agency and to its staff;
Whereas Article 75 of Regulation (EC) No 726/2004 provides that the Staff Regulations
of officials of the European Union, the Conditions of Employment of Other Servants
of the European Union and the rules adopted jointly by the institutions of the European
Union for the purposes of the application of those Staff Regulations and Conditions
of Employment shall apply to the staff of the Agency;
Whereas further administrative provisions must be agreed for the implementation of
the Protocol, in particular to lay down conditions concerning the privileges, immunities, facilities,
and services of and related to the Agency and its staff in the territory of the Kingdom
of the Netherlands as necessary for the fulfilment of the purposes of the Agency;